Quote | Talaris Therapeutics Inc. (NASDAQ:TALS)
Last: | $2.72 |
---|---|
Change Percent: | -1.46% |
Open: | $2.78 |
Close: | $2.72 |
High: | $2.795 |
Low: | $2.69 |
Volume: | 299,250 |
Last Trade Date Time: | 10/19/2023 03:00:00 am |
News | Talaris Therapeutics Inc. (NASDAQ:TALS)
2023-10-19 11:16:03 ET Talaris Therapeutics ( NASDAQ: TALS ) had declared $1.5118/share special dividend . Payable Oct. 20; for shareholders of record Oct. 16; ex-div Oct. 20. See TALS Dividend Scorecard, Yield Chart, & Dividend Growth. For further detail...
2023-10-17 18:51:58 ET More on Talaris Therapeutics Talaris sells kidney transplant asset FCR001 to ImmunoFree Seeking Alpha’s Quant Rating on Talaris Therapeutics Historical earnings data for Talaris Therapeutics Financial information for Talaris Ther...
Message Board Posts | Talaris Therapeutics Inc. (NASDAQ:TALS)
Subject | By | Source | When |
---|---|---|---|
Relative buying vol up 120Xs,one of highest in | 81vette | investorshub | 06/22/2023 3:55:26 PM |
Up 160% this year,6 month trend now revealed | 81vette | investorshub | 06/22/2023 3:38:13 PM |
Book pps 3.87,analysts target 7,50,GOLDEN CROSS!!,confirms bullish trend | 81vette | investorshub | 06/22/2023 3:20:29 PM |
210M cash coming,strong balance sheet.3 clinical trials,all phase 2 | 81vette | investorshub | 06/22/2023 3:08:56 PM |
Merger,900k short,shares to short dropping, 35%today,going to run | 81vette | investorshub | 06/22/2023 3:03:11 PM |
News, Short Squeeze, Breakout and More Instantly...
Talaris Therapeutics Inc. Company Name:
TALS Stock Symbol:
NASDAQ Market:
Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special...
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “C...
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, a...